TrialNature communications2025

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

Mariano Provencio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.